No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
Leerink Partners Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Raises Target Price to $24
Stoke Therapeutics Price Target Announced at $24.00/Share by Chardan Capital
Stoke Therapeutics Initiated at Buy by Chardan Capital
Companies Like Stoke Therapeutics (NASDAQ:STOK) Are In A Position To Invest In Growth
Stoke Therapeutics (NASDAQ:STOK) Pulls Back 9.1% This Week, but Still Delivers Shareholders Impressive 136% Return Over 1 Year
Cantor Fitzgerald Reiterates Overweight on Stoke Therapeuticsto Overweight